01
Advanced Biosensor Engineering
Leveraging semiconductor manufacturing expertise for highly sensitive diagnostic platforms.
Semiconductor-Powered Precision Diagnostics
Ultra-sensitive biochip platform for rapid and early disease detection.
0
Patents granted and pending
2.4 billion
Sensors per Biochip
Contact Our Team
- +886 3 560 0660
0
+
Biochips Tested as of May 31, 2026
Pioneering Semiconductor-Based Precision Diagnostics
Novascope is a semiconductor-driven biotech company developing ultra-sensitive biochip technologies for rapid disease detection, precision diagnostics, and next-generation healthcare applications.
Founder & Executive Team
Our proprietary semiconductor biosensor platform enables highly sensitive biomarker detection with the speed, scalability, and precision needed for future clinical diagnostics.
Semiconductor Biochip Platform
Advanced nano-biosensor technology designed for ultra-sensitive biomarker detection.
Rapid Sepsis Diagnostics
Enabling fast and accurate sepsis detection within clinically critical timelines.
Alzheimer’s Detection Pipeline
Developing next-generation diagnostic tools for early neurodegenerative disease detection.
Precision Diagnostic Solutions
Scalable diagnostic technologies supporting future clinical and healthcare applications.
Silicon IP
0
%
Bio Development Programs
0
Advancing next-generation precision diagnostics through semiconductor innovation.
02
Rapid Diagnostic Development
Accelerating disease detection workflows with fast and scalable biochip technologies.
03
Precision Medicine Applications
Supporting future healthcare innovation with data-driven precision diagnostic systems.
Revolutionary Technology Platform & Research Insights
Where Silicon Meets Biology
The First Bio-Fabless Diagnostics
Semiconductor IC Design Model Applied to In-Vitro Diagnostics
Request Investor Deck : ir@novascopedx.com
Novascope is a semiconductor-driven biotech company developing ultra-sensitive biochips for rapid, early disease detection and precision diagnostics
© 2026 Novascope Diagnostics Inc.